Search company, investor...
Neopharmed Gentili company logo

Neopharmed Gentili

Founded Year



Acq - Fin - II | Alive

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+40 points in the past 30 days

About Neopharmed Gentili

Neopharmed Gentili research develops and distributes medicines to its clients in the pharmaceutical market. It sells the anticancer drug for women with breast cancer and for promoting an antitumor drug for patients with ALK+ pulmonary carcinoma. The company was founded in 2017 and is based in Milan, Italy.

Headquarters Location

S.G. Cottolengo, 15

Milan, 20143,


+39 0289132600

Missing: Neopharmed Gentili's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neopharmed Gentili's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Neopharmed Gentili News

CVC Credit supports Neopharmed Gentili

Mar 21, 2023

13 February 2023 CVC Credit is pleased to announce that it has committed senior and acquisition facilities to support Ardian with its renewed investment into leading Italian pharmaceutical group, Neopharmed Gentili ("Neopharmed"), while also supporting NB Renaissance's fresh investment into the company. Neopharmed is a market leader in therapeutic areas such as cardiovascular and neurology, and employs one of the largest networks of pharma representatives in Italy. During the partnership with Ardian, Neopharmed pursued a long-term growth strategy, expanding both organically and through an ambitious buy-and-build plan, which resulted in six M&A transactions in four years. This growth plan also saw the business strengthen and diversify its product portfolio, achieving revenues of €200m. We see strong future growth and performance prospects for the group Simone Zacchi Managing Director, CVC Simone Zacchi, Managing Director at CVC Credit said: "Neopharmed is an Italian champion with steady and predictable revenues, which has historically outperformed the market, as a result of its powerful brand recognition, high quality products and large commercial salesforce that covers the majority of GPs in Italy. As a proven consolidator and as a fast-growing business under Ardian's stewardship, and now with the added support of NB Renaissance, we see strong future growth and performance prospects for the group." Andrew Davies, Managing Partner and Co-Head of Private Credit at CVC Credit added: "We are very pleased to be partnering with Ardian and NB Renaissance for the first time. We are confident that Neopharmed's impressive outperformance of the Italian pharmaceutical market will continue, with the company capitalising on its synergistic platform to achieve sector-leading margins." Latest news

Neopharmed Gentili Frequently Asked Questions (FAQ)

  • When was Neopharmed Gentili founded?

    Neopharmed Gentili was founded in 2017.

  • Where is Neopharmed Gentili's headquarters?

    Neopharmed Gentili's headquarters is located at S.G. Cottolengo, 15, Milan.

  • What is Neopharmed Gentili's latest funding round?

    Neopharmed Gentili's latest funding round is Acq - Fin - II.

  • Who are the investors of Neopharmed Gentili?

    Investors of Neopharmed Gentili include Ardian and NB Renaissance Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.